BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 36763374)

  • 1. Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies.
    Pal Chaudhary S; Reyes S; Chase ML; Govindan A; Zhao L; Luther J; Bhan I; Bethea E; Franses JW; Paige Walsh E; Anne Dageford L; Kimura S; Elias N; Yeh H; Markman J; Bozorgzadeh A; Tanabe K; Ferrone C; Zhu AX; Andersson K; Thiim M; Antonio Catalano O; Kambadakone A; Vagefi PA; Qadan M; Pratt D; Hashemi N; Corey KE; Misdraji J; Goyal L; Clark JW
    Oncologist; 2023 Apr; 28(4):341-350. PubMed ID: 36763374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
    Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
    Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.
    Koh YX; Tan HJ; Liew YX; Syn N; Teo JY; Lee SY; Goh BKP; Goh GBB; Chan CY
    J Am Coll Surg; 2019 Nov; 229(5):467-478.e1. PubMed ID: 31398386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
    Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
    Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC.
    Yang T; Hu LY; Li ZL; Liu K; Wu H; Xing H; Lau WY; Pawlik TM; Zeng YY; Zhou YH; Gu WM; Wang H; Chen TH; Han J; Li C; Wang MD; Wu MC; Shen F
    J Gastrointest Surg; 2020 Feb; 24(2):320-329. PubMed ID: 30617773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
    Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Type 2 Diabetes on Oncologic Outcomes of Hepatocellular Carcinomas in Non-Cirrhotic, Non-alcoholic Steatohepatitis: a Matched-Pair Analysis.
    Billeter AT; Müller PC; Albrecht T; Roessler S; Löffler M; Lemekhova A; Mehrabi A; Müller-Stich BP; Hoffmann K
    J Gastrointest Surg; 2021 May; 25(5):1193-1202. PubMed ID: 32378092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease is associated with heterogeneous pattern of fat infiltration in skeletal muscles.
    Nachit M; Dioguardi Burgio M; Abyzov A; Garteiser P; Paradis V; Vilgrain V; Leclercq I; Van Beers BE
    Eur Radiol; 2024 Mar; 34(3):1461-1470. PubMed ID: 37658893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis.
    Young S; Sanghvi T; Rubin N; Hall D; Roller L; Charaf Y; Golzarian J
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):65-75. PubMed ID: 31686136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.
    Ertle J; Dechêne A; Sowa JP; Penndorf V; Herzer K; Kaiser G; Schlaak JF; Gerken G; Syn WK; Canbay A
    Int J Cancer; 2011 May; 128(10):2436-43. PubMed ID: 21128245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
    Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
    Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
    Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
    Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma.
    Vachher M; Bansal S; Kumar B; Yadav S; Arora T; Wali NM; Burman A
    J Cell Biochem; 2022 Oct; 123(10):1553-1584. PubMed ID: 35818831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.
    Tobari M; Hashimoto E; Taniai M; Kodama K; Kogiso T; Tokushige K; Yamamoto M; Takayoshi N; Satoshi K; Tatsuo A
    J Gastroenterol Hepatol; 2020 May; 35(5):862-869. PubMed ID: 31597206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Serum Oxidative/Anti-oxidative Stress Balance Becomes Dysregulated in Patients with Non-alcoholic Steatohepatitis Associated with Hepatocellular Carcinoma.
    Shimomura Y; Takaki A; Wada N; Yasunaka T; Ikeda F; Maruyama T; Tamaki N; Uchida D; Onishi H; Kuwaki K; Nakamura S; Nouso K; Miyake Y; Koike K; Tomofuji T; Morita M; Yamamoto K; Okada H
    Intern Med; 2017; 56(3):243-251. PubMed ID: 28154266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
    Kodama K; Kawaguchi T; Hyogo H; Nakajima T; Ono M; Seike M; Takahashi H; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Seko Y; Takehara T; Itoh Y; Nakajima A; Masaki N; Torimura T; Saibara T; Karino Y; Chayama K; Tokushige K
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1626-1632. PubMed ID: 30668889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.